Application Nr Approved Date Route Status External Links
NDA020839 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Plavix Is A P2y 12 Platelet Inhibitor Indicated For: Acute Coronary Syndrome – For Patients With Non–st-Segment Elevation Acs (Unstable Angina [Ua]/non–st-Elevation Myocardial Infarction [Nstemi]), Plavix Has Been Shown To Reduce The Rate Of Myocardial Infarction (Mi) And Stroke. ( 1.1 ) – For Patients With St-Elevation Myocardial Infarction (Stemi), Plavix Has Been Shown To Reduce The Rate Of Mi And Stroke. ( 1.1 ) Recent Mi, Recent Stroke, Or Established Peripheral Arterial Disease. Plavix Has Been Shown To Reduce The Rate Of Mi And Stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (Acs) Plavix Is Indicated To Reduce The Rate Of Myocardial Infarction (Mi) And Stroke In Patients With Non–st-Segment Elevation Acs (Unstable Angina [Ua]/non–st-Elevation Myocardial Infarction [Nstemi]), Including Patients Who Are To Be Managed Medically And Those Who Are To Be Managed With Coronary Revascularization. Plavix Should Be Administered In Conjunction With Aspirin. Plavix Is Indicated To Reduce The Rate Of Myocardial Infarction And Stroke In Patients With Acute St-Elevation Myocardial Infarction (Stemi) Who Are To Be Managed Medically. Plavix Should Be Administered In Conjunction With Aspirin. 1.2 Recent Mi, Recent Stroke, Or Established Peripheral Arterial Disease In Patients With Established Peripheral Arterial Disease Or With A History Of Recent Myocardial Infarction (Mi) Or Recent Stroke Plavix Is Indicated To Reduce The Rate Of Mi And Stroke.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Clopidogrel Bisulfate CLOPIDOGREL BISULFATE ZINC34781704

Comments